Abstract
The inhibitor of growth (ING) gene family proteins regulate many critical cellular processes such as cell proliferation and growth, apoptosis, DNA repair, senescence, angiogenesis, and drug resistance. Their transcripts and proteins are differentially expressed in health and disease and there is evidence for developmental regulation. The vast majority of studies have characterized ING levels in the context of cancer. However, relatively little attention has been paid to the expression of ING family members in other contexts. This review summarizes the findings from human and animal model systems that provide insight into the factors influencing the expression of these important proteins. We examine the influence of cell cycle and aging as well as genotoxic stress on ING expression levels and evaluate several emerging areas of inquiry demonstrating that ING gene activity may be modulated by factors such as the p53 tumor suppressor, DNA methylation, and ING proteins themselves with external factors such as hormones, reactive oxygen species, TGFβ signalling, and other proteins of pathological significance also influencing ING levels. We then briefly discuss the influence of posttranslational modification and changes in subcellular localization as it pertains to modulation of ING expression. Understanding how ING expression is modulated represents a vital aspect of effective drug targeting strategies.
Keywords: ING1, ING2, ING3, ING4, ING5, transcript variant, regulation, protein
Current Drug Targets
Title: Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Volume: 10 Issue: 5
Author(s): Stacey K. Maher and Caren C. Helbing
Affiliation:
Keywords: ING1, ING2, ING3, ING4, ING5, transcript variant, regulation, protein
Abstract: The inhibitor of growth (ING) gene family proteins regulate many critical cellular processes such as cell proliferation and growth, apoptosis, DNA repair, senescence, angiogenesis, and drug resistance. Their transcripts and proteins are differentially expressed in health and disease and there is evidence for developmental regulation. The vast majority of studies have characterized ING levels in the context of cancer. However, relatively little attention has been paid to the expression of ING family members in other contexts. This review summarizes the findings from human and animal model systems that provide insight into the factors influencing the expression of these important proteins. We examine the influence of cell cycle and aging as well as genotoxic stress on ING expression levels and evaluate several emerging areas of inquiry demonstrating that ING gene activity may be modulated by factors such as the p53 tumor suppressor, DNA methylation, and ING proteins themselves with external factors such as hormones, reactive oxygen species, TGFβ signalling, and other proteins of pathological significance also influencing ING levels. We then briefly discuss the influence of posttranslational modification and changes in subcellular localization as it pertains to modulation of ING expression. Understanding how ING expression is modulated represents a vital aspect of effective drug targeting strategies.
Export Options
About this article
Cite this article as:
Maher K. Stacey and Helbing C. Caren, Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease, Current Drug Targets 2009; 10 (5) . https://dx.doi.org/10.2174/138945009788185095
DOI https://dx.doi.org/10.2174/138945009788185095 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Meet Our Editor:
Current Cardiology Reviews Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design Folding, Assembly, and Stability of Transmembrane Cytochromes
Current Chemical Biology Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Management of Cardiogenic Shock due to Thyrotoxicosis: A Systematic Literature Review
Current Cardiology Reviews Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Polyamines and Related Nitrogen Compounds in the Chemotherapy of Neglected Diseases Caused by Kinetoplastids
Current Topics in Medicinal Chemistry Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Ferroptotic Cell Death: New Regulatory Mechanisms for Metabolic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology ACE2 and Diabetic Complications
Current Pharmaceutical Design Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design